nodes	percent_of_prediction	percent_of_DWPC	metapath
Nefazodone—ABCB1—esophageal cancer	0.555	1	CbGaD
Nefazodone—Oesophagitis—Capecitabine—esophageal cancer	0.00123	0.00514	CcSEcCtD
Nefazodone—Mouth ulceration—Capecitabine—esophageal cancer	0.00122	0.00509	CcSEcCtD
Nefazodone—Urine output increased—Capecitabine—esophageal cancer	0.00122	0.00509	CcSEcCtD
Nefazodone—Ecchymosis—Capecitabine—esophageal cancer	0.00122	0.00509	CcSEcCtD
Nefazodone—Orthostatic hypotension—Cisplatin—esophageal cancer	0.00121	0.00506	CcSEcCtD
Nefazodone—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.00119	0.00499	CcSEcCtD
Nefazodone—Cramp muscle—Cisplatin—esophageal cancer	0.00119	0.00499	CcSEcCtD
Nefazodone—Abnormal vision—Capecitabine—esophageal cancer	0.00117	0.00491	CcSEcCtD
Nefazodone—Mental disability—Capecitabine—esophageal cancer	0.00117	0.00488	CcSEcCtD
Nefazodone—Ear pain—Capecitabine—esophageal cancer	0.00115	0.00479	CcSEcCtD
Nefazodone—Musculoskeletal stiffness—Methotrexate—esophageal cancer	0.00112	0.00467	CcSEcCtD
Nefazodone—Polyuria—Capecitabine—esophageal cancer	0.00111	0.00465	CcSEcCtD
Nefazodone—Gastroenteritis—Capecitabine—esophageal cancer	0.0011	0.00461	CcSEcCtD
Nefazodone—Deafness—Capecitabine—esophageal cancer	0.00109	0.00456	CcSEcCtD
Nefazodone—Oliguria—Methotrexate—esophageal cancer	0.00109	0.00454	CcSEcCtD
Nefazodone—Glossitis—Methotrexate—esophageal cancer	0.00109	0.00454	CcSEcCtD
Nefazodone—Hepatic failure—Capecitabine—esophageal cancer	0.00109	0.00454	CcSEcCtD
Nefazodone—Eye pain—Capecitabine—esophageal cancer	0.00108	0.00452	CcSEcCtD
Nefazodone—Dysarthria—Methotrexate—esophageal cancer	0.00106	0.00443	CcSEcCtD
Nefazodone—Libido decreased—Capecitabine—esophageal cancer	0.00105	0.0044	CcSEcCtD
Nefazodone—Increased appetite—Capecitabine—esophageal cancer	0.00104	0.00435	CcSEcCtD
Nefazodone—Thirst—Capecitabine—esophageal cancer	0.00103	0.00429	CcSEcCtD
Nefazodone—Dermatitis bullous—Capecitabine—esophageal cancer	0.00102	0.00427	CcSEcCtD
Nefazodone—Arthritis—Capecitabine—esophageal cancer	0.00101	0.0042	CcSEcCtD
Nefazodone—Vaginal inflammation—Methotrexate—esophageal cancer	0.001	0.00419	CcSEcCtD
Nefazodone—Cerebrovascular accident—Capecitabine—esophageal cancer	0.000998	0.00417	CcSEcCtD
Nefazodone—Stomatitis—Cisplatin—esophageal cancer	0.000996	0.00416	CcSEcCtD
Nefazodone—Conjunctivitis—Cisplatin—esophageal cancer	0.000993	0.00415	CcSEcCtD
Nefazodone—Hyponatraemia—Capecitabine—esophageal cancer	0.000982	0.0041	CcSEcCtD
Nefazodone—Cystitis noninfective—Methotrexate—esophageal cancer	0.000979	0.00409	CcSEcCtD
Nefazodone—Osteoarthritis—Capecitabine—esophageal cancer	0.000978	0.00408	CcSEcCtD
Nefazodone—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.000978	0.00408	CcSEcCtD
Nefazodone—Diplopia—Capecitabine—esophageal cancer	0.000978	0.00408	CcSEcCtD
Nefazodone—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.00097	0.00405	CcSEcCtD
Nefazodone—Cystitis—Methotrexate—esophageal cancer	0.000968	0.00404	CcSEcCtD
Nefazodone—Migraine—Capecitabine—esophageal cancer	0.000962	0.00402	CcSEcCtD
Nefazodone—Vaginal infection—Methotrexate—esophageal cancer	0.000946	0.00395	CcSEcCtD
Nefazodone—Face oedema—Capecitabine—esophageal cancer	0.000944	0.00394	CcSEcCtD
Nefazodone—Bradycardia—Cisplatin—esophageal cancer	0.000934	0.0039	CcSEcCtD
Nefazodone—Urinary retention—Capecitabine—esophageal cancer	0.00093	0.00388	CcSEcCtD
Nefazodone—Mood swings—Capecitabine—esophageal cancer	0.000926	0.00387	CcSEcCtD
Nefazodone—Ataxia—Capecitabine—esophageal cancer	0.000919	0.00384	CcSEcCtD
Nefazodone—Dehydration—Capecitabine—esophageal cancer	0.000909	0.0038	CcSEcCtD
Nefazodone—Ecchymosis—Methotrexate—esophageal cancer	0.000906	0.00379	CcSEcCtD
Nefazodone—Mouth ulceration—Methotrexate—esophageal cancer	0.000906	0.00379	CcSEcCtD
Nefazodone—Bladder pain—Methotrexate—esophageal cancer	0.000906	0.00379	CcSEcCtD
Nefazodone—Urine output increased—Methotrexate—esophageal cancer	0.000906	0.00379	CcSEcCtD
Nefazodone—Liver function test abnormal—Capecitabine—esophageal cancer	0.000903	0.00377	CcSEcCtD
Nefazodone—Gynaecomastia—Methotrexate—esophageal cancer	0.000897	0.00375	CcSEcCtD
Nefazodone—Dry skin—Capecitabine—esophageal cancer	0.000896	0.00374	CcSEcCtD
Nefazodone—Orthostatic hypotension—Capecitabine—esophageal cancer	0.000893	0.00373	CcSEcCtD
Nefazodone—Visual impairment—Cisplatin—esophageal cancer	0.000884	0.00369	CcSEcCtD
Nefazodone—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.00088	0.00368	CcSEcCtD
Nefazodone—Gastritis—Capecitabine—esophageal cancer	0.000865	0.00361	CcSEcCtD
Nefazodone—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000862	0.0036	CcSEcCtD
Nefazodone—Tinnitus—Cisplatin—esophageal cancer	0.000855	0.00357	CcSEcCtD
Nefazodone—Lymphadenopathy—Methotrexate—esophageal cancer	0.000853	0.00356	CcSEcCtD
Nefazodone—Flushing—Cisplatin—esophageal cancer	0.000851	0.00356	CcSEcCtD
Nefazodone—Abdominal distension—Capecitabine—esophageal cancer	0.000851	0.00355	CcSEcCtD
Nefazodone—Influenza—Capecitabine—esophageal cancer	0.000845	0.00353	CcSEcCtD
Nefazodone—Dysphagia—Capecitabine—esophageal cancer	0.000845	0.00353	CcSEcCtD
Nefazodone—Asthma—Capecitabine—esophageal cancer	0.000845	0.00353	CcSEcCtD
Nefazodone—Polyuria—Methotrexate—esophageal cancer	0.000829	0.00346	CcSEcCtD
Nefazodone—Angina pectoris—Capecitabine—esophageal cancer	0.000823	0.00344	CcSEcCtD
Nefazodone—Bronchitis—Capecitabine—esophageal cancer	0.000813	0.00339	CcSEcCtD
Nefazodone—Alopecia—Cisplatin—esophageal cancer	0.000811	0.00339	CcSEcCtD
Nefazodone—Hepatic failure—Methotrexate—esophageal cancer	0.00081	0.00338	CcSEcCtD
Nefazodone—Dysuria—Capecitabine—esophageal cancer	0.00079	0.0033	CcSEcCtD
Nefazodone—Flatulence—Cisplatin—esophageal cancer	0.000787	0.00329	CcSEcCtD
Nefazodone—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000771	0.00322	CcSEcCtD
Nefazodone—Weight increased—Capecitabine—esophageal cancer	0.000769	0.00321	CcSEcCtD
Nefazodone—Visual disturbance—Methotrexate—esophageal cancer	0.000768	0.00321	CcSEcCtD
Nefazodone—Muscle spasms—Cisplatin—esophageal cancer	0.000768	0.00321	CcSEcCtD
Nefazodone—Weight decreased—Capecitabine—esophageal cancer	0.000764	0.00319	CcSEcCtD
Nefazodone—Pneumonia—Capecitabine—esophageal cancer	0.000758	0.00316	CcSEcCtD
Nefazodone—Vision blurred—Cisplatin—esophageal cancer	0.000753	0.00314	CcSEcCtD
Nefazodone—Tremor—Cisplatin—esophageal cancer	0.000748	0.00313	CcSEcCtD
Nefazodone—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000747	0.00312	CcSEcCtD
Nefazodone—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000743	0.0031	CcSEcCtD
Nefazodone—Ill-defined disorder—Cisplatin—esophageal cancer	0.000741	0.00309	CcSEcCtD
Nefazodone—Anaemia—Cisplatin—esophageal cancer	0.000738	0.00308	CcSEcCtD
Nefazodone—Stomatitis—Capecitabine—esophageal cancer	0.000734	0.00307	CcSEcCtD
Nefazodone—Urinary tract infection—Capecitabine—esophageal cancer	0.000732	0.00306	CcSEcCtD
Nefazodone—Conjunctivitis—Capecitabine—esophageal cancer	0.000732	0.00306	CcSEcCtD
Nefazodone—Osteoarthritis—Methotrexate—esophageal cancer	0.000728	0.00304	CcSEcCtD
Nefazodone—Malaise—Cisplatin—esophageal cancer	0.00072	0.00301	CcSEcCtD
Nefazodone—Haematuria—Capecitabine—esophageal cancer	0.000718	0.003	CcSEcCtD
Nefazodone—Leukopenia—Cisplatin—esophageal cancer	0.000715	0.00299	CcSEcCtD
Nefazodone—Epistaxis—Capecitabine—esophageal cancer	0.000711	0.00297	CcSEcCtD
Nefazodone—Convulsion—Cisplatin—esophageal cancer	0.000692	0.00289	CcSEcCtD
Nefazodone—Mood swings—Methotrexate—esophageal cancer	0.000689	0.00288	CcSEcCtD
Nefazodone—Bradycardia—Capecitabine—esophageal cancer	0.000688	0.00288	CcSEcCtD
Nefazodone—Ataxia—Methotrexate—esophageal cancer	0.000684	0.00286	CcSEcCtD
Nefazodone—Myalgia—Cisplatin—esophageal cancer	0.00068	0.00284	CcSEcCtD
Nefazodone—Haemoglobin—Capecitabine—esophageal cancer	0.00068	0.00284	CcSEcCtD
Nefazodone—Rhinitis—Capecitabine—esophageal cancer	0.000678	0.00283	CcSEcCtD
Nefazodone—Anxiety—Cisplatin—esophageal cancer	0.000678	0.00283	CcSEcCtD
Nefazodone—Haemorrhage—Capecitabine—esophageal cancer	0.000676	0.00282	CcSEcCtD
Nefazodone—Hepatitis—Capecitabine—esophageal cancer	0.000676	0.00282	CcSEcCtD
Nefazodone—Hypoaesthesia—Capecitabine—esophageal cancer	0.000673	0.00281	CcSEcCtD
Nefazodone—Liver function test abnormal—Methotrexate—esophageal cancer	0.000672	0.00281	CcSEcCtD
Nefazodone—Discomfort—Cisplatin—esophageal cancer	0.000672	0.00281	CcSEcCtD
Nefazodone—Pharyngitis—Capecitabine—esophageal cancer	0.000671	0.0028	CcSEcCtD
Nefazodone—Oedema peripheral—Capecitabine—esophageal cancer	0.000666	0.00278	CcSEcCtD
Nefazodone—Oedema—Cisplatin—esophageal cancer	0.000652	0.00272	CcSEcCtD
Nefazodone—Anaphylactic shock—Cisplatin—esophageal cancer	0.000652	0.00272	CcSEcCtD
Nefazodone—Visual impairment—Capecitabine—esophageal cancer	0.000652	0.00272	CcSEcCtD
Nefazodone—Infection—Cisplatin—esophageal cancer	0.000648	0.0027	CcSEcCtD
Nefazodone—Erythema multiforme—Capecitabine—esophageal cancer	0.000639	0.00267	CcSEcCtD
Nefazodone—Thrombocytopenia—Cisplatin—esophageal cancer	0.000638	0.00267	CcSEcCtD
Nefazodone—Tachycardia—Cisplatin—esophageal cancer	0.000636	0.00266	CcSEcCtD
Nefazodone—Tinnitus—Capecitabine—esophageal cancer	0.000631	0.00263	CcSEcCtD
Nefazodone—Hyperhidrosis—Cisplatin—esophageal cancer	0.00063	0.00263	CcSEcCtD
Nefazodone—Asthma—Methotrexate—esophageal cancer	0.000629	0.00263	CcSEcCtD
Nefazodone—Flushing—Capecitabine—esophageal cancer	0.000628	0.00262	CcSEcCtD
Nefazodone—Anorexia—Cisplatin—esophageal cancer	0.000621	0.00259	CcSEcCtD
Nefazodone—Hypotension—Cisplatin—esophageal cancer	0.000609	0.00254	CcSEcCtD
Nefazodone—Chills—Capecitabine—esophageal cancer	0.000607	0.00253	CcSEcCtD
Nefazodone—Alopecia—Capecitabine—esophageal cancer	0.000598	0.0025	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000594	0.00248	CcSEcCtD
Nefazodone—Dysuria—Methotrexate—esophageal cancer	0.000588	0.00246	CcSEcCtD
Nefazodone—Paraesthesia—Cisplatin—esophageal cancer	0.000585	0.00244	CcSEcCtD
Nefazodone—Dyspnoea—Cisplatin—esophageal cancer	0.000581	0.00243	CcSEcCtD
Nefazodone—Flatulence—Capecitabine—esophageal cancer	0.00058	0.00242	CcSEcCtD
Nefazodone—Erectile dysfunction—Methotrexate—esophageal cancer	0.000579	0.00242	CcSEcCtD
Nefazodone—Dysgeusia—Capecitabine—esophageal cancer	0.000577	0.00241	CcSEcCtD
Nefazodone—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000574	0.0024	CcSEcCtD
Nefazodone—Back pain—Capecitabine—esophageal cancer	0.000569	0.00238	CcSEcCtD
Nefazodone—Decreased appetite—Cisplatin—esophageal cancer	0.000567	0.00237	CcSEcCtD
Nefazodone—Muscle spasms—Capecitabine—esophageal cancer	0.000566	0.00236	CcSEcCtD
Nefazodone—Pneumonia—Methotrexate—esophageal cancer	0.000564	0.00236	CcSEcCtD
Nefazodone—Pain—Cisplatin—esophageal cancer	0.000557	0.00233	CcSEcCtD
Nefazodone—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000556	0.00232	CcSEcCtD
Nefazodone—Vision blurred—Capecitabine—esophageal cancer	0.000555	0.00232	CcSEcCtD
Nefazodone—Tremor—Capecitabine—esophageal cancer	0.000552	0.0023	CcSEcCtD
Nefazodone—Stomatitis—Methotrexate—esophageal cancer	0.000547	0.00228	CcSEcCtD
Nefazodone—Ill-defined disorder—Capecitabine—esophageal cancer	0.000546	0.00228	CcSEcCtD
Nefazodone—Conjunctivitis—Methotrexate—esophageal cancer	0.000545	0.00228	CcSEcCtD
Nefazodone—Anaemia—Capecitabine—esophageal cancer	0.000544	0.00227	CcSEcCtD
Nefazodone—Sweating—Methotrexate—esophageal cancer	0.000538	0.00225	CcSEcCtD
Nefazodone—Feeling abnormal—Cisplatin—esophageal cancer	0.000537	0.00224	CcSEcCtD
Nefazodone—Haematuria—Methotrexate—esophageal cancer	0.000535	0.00223	CcSEcCtD
Nefazodone—Malaise—Capecitabine—esophageal cancer	0.000531	0.00222	CcSEcCtD
Nefazodone—Epistaxis—Methotrexate—esophageal cancer	0.000529	0.00221	CcSEcCtD
Nefazodone—Vertigo—Capecitabine—esophageal cancer	0.000529	0.00221	CcSEcCtD
Nefazodone—Syncope—Capecitabine—esophageal cancer	0.000528	0.0022	CcSEcCtD
Nefazodone—Leukopenia—Capecitabine—esophageal cancer	0.000527	0.0022	CcSEcCtD
Nefazodone—Palpitations—Capecitabine—esophageal cancer	0.00052	0.00217	CcSEcCtD
Nefazodone—Loss of consciousness—Capecitabine—esophageal cancer	0.000517	0.00216	CcSEcCtD
Nefazodone—Body temperature increased—Cisplatin—esophageal cancer	0.000515	0.00215	CcSEcCtD
Nefazodone—Cough—Capecitabine—esophageal cancer	0.000514	0.00215	CcSEcCtD
Nefazodone—Hypertension—Capecitabine—esophageal cancer	0.000508	0.00212	CcSEcCtD
Nefazodone—Haemoglobin—Methotrexate—esophageal cancer	0.000506	0.00211	CcSEcCtD
Nefazodone—Hepatitis—Methotrexate—esophageal cancer	0.000503	0.0021	CcSEcCtD
Nefazodone—Haemorrhage—Methotrexate—esophageal cancer	0.000503	0.0021	CcSEcCtD
Nefazodone—Arthralgia—Capecitabine—esophageal cancer	0.000501	0.00209	CcSEcCtD
Nefazodone—Myalgia—Capecitabine—esophageal cancer	0.000501	0.00209	CcSEcCtD
Nefazodone—Chest pain—Capecitabine—esophageal cancer	0.000501	0.00209	CcSEcCtD
Nefazodone—Pharyngitis—Methotrexate—esophageal cancer	0.0005	0.00209	CcSEcCtD
Nefazodone—Anxiety—Capecitabine—esophageal cancer	0.000499	0.00209	CcSEcCtD
Nefazodone—Discomfort—Capecitabine—esophageal cancer	0.000495	0.00207	CcSEcCtD
Nefazodone—Dry mouth—Capecitabine—esophageal cancer	0.00049	0.00205	CcSEcCtD
Nefazodone—Visual impairment—Methotrexate—esophageal cancer	0.000485	0.00203	CcSEcCtD
Nefazodone—Confusional state—Capecitabine—esophageal cancer	0.000484	0.00202	CcSEcCtD
Nefazodone—Oedema—Capecitabine—esophageal cancer	0.00048	0.00201	CcSEcCtD
Nefazodone—Hypersensitivity—Cisplatin—esophageal cancer	0.00048	0.00201	CcSEcCtD
Nefazodone—Infection—Capecitabine—esophageal cancer	0.000477	0.00199	CcSEcCtD
Nefazodone—Erythema multiforme—Methotrexate—esophageal cancer	0.000476	0.00199	CcSEcCtD
Nefazodone—Shock—Capecitabine—esophageal cancer	0.000473	0.00197	CcSEcCtD
Nefazodone—Thrombocytopenia—Capecitabine—esophageal cancer	0.00047	0.00196	CcSEcCtD
Nefazodone—Tinnitus—Methotrexate—esophageal cancer	0.000469	0.00196	CcSEcCtD
Nefazodone—Tachycardia—Capecitabine—esophageal cancer	0.000469	0.00196	CcSEcCtD
Nefazodone—Asthenia—Cisplatin—esophageal cancer	0.000468	0.00195	CcSEcCtD
Nefazodone—Hyperhidrosis—Capecitabine—esophageal cancer	0.000464	0.00194	CcSEcCtD
Nefazodone—Anorexia—Capecitabine—esophageal cancer	0.000458	0.00191	CcSEcCtD
Nefazodone—Chills—Methotrexate—esophageal cancer	0.000452	0.00189	CcSEcCtD
Nefazodone—Hypotension—Capecitabine—esophageal cancer	0.000449	0.00188	CcSEcCtD
Nefazodone—Diarrhoea—Cisplatin—esophageal cancer	0.000446	0.00186	CcSEcCtD
Nefazodone—Alopecia—Methotrexate—esophageal cancer	0.000445	0.00186	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000438	0.00183	CcSEcCtD
Nefazodone—Insomnia—Capecitabine—esophageal cancer	0.000435	0.00181	CcSEcCtD
Nefazodone—Paraesthesia—Capecitabine—esophageal cancer	0.000431	0.0018	CcSEcCtD
Nefazodone—Dysgeusia—Methotrexate—esophageal cancer	0.000429	0.00179	CcSEcCtD
Nefazodone—Dyspnoea—Capecitabine—esophageal cancer	0.000428	0.00179	CcSEcCtD
Nefazodone—Back pain—Methotrexate—esophageal cancer	0.000424	0.00177	CcSEcCtD
Nefazodone—Dyspepsia—Capecitabine—esophageal cancer	0.000423	0.00177	CcSEcCtD
Nefazodone—Decreased appetite—Capecitabine—esophageal cancer	0.000418	0.00174	CcSEcCtD
Nefazodone—Vomiting—Cisplatin—esophageal cancer	0.000414	0.00173	CcSEcCtD
Nefazodone—Vision blurred—Methotrexate—esophageal cancer	0.000413	0.00173	CcSEcCtD
Nefazodone—Rash—Cisplatin—esophageal cancer	0.000411	0.00172	CcSEcCtD
Nefazodone—Constipation—Capecitabine—esophageal cancer	0.000411	0.00172	CcSEcCtD
Nefazodone—Pain—Capecitabine—esophageal cancer	0.000411	0.00172	CcSEcCtD
Nefazodone—Dermatitis—Cisplatin—esophageal cancer	0.000411	0.00171	CcSEcCtD
Nefazodone—Ill-defined disorder—Methotrexate—esophageal cancer	0.000407	0.0017	CcSEcCtD
Nefazodone—Anaemia—Methotrexate—esophageal cancer	0.000405	0.00169	CcSEcCtD
Nefazodone—Feeling abnormal—Capecitabine—esophageal cancer	0.000396	0.00165	CcSEcCtD
Nefazodone—Malaise—Methotrexate—esophageal cancer	0.000395	0.00165	CcSEcCtD
Nefazodone—Vertigo—Methotrexate—esophageal cancer	0.000394	0.00164	CcSEcCtD
Nefazodone—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000393	0.00164	CcSEcCtD
Nefazodone—Leukopenia—Methotrexate—esophageal cancer	0.000392	0.00164	CcSEcCtD
Nefazodone—Nausea—Cisplatin—esophageal cancer	0.000387	0.00162	CcSEcCtD
Nefazodone—Cough—Methotrexate—esophageal cancer	0.000382	0.0016	CcSEcCtD
Nefazodone—Urticaria—Capecitabine—esophageal cancer	0.000382	0.00159	CcSEcCtD
Nefazodone—Abdominal pain—Capecitabine—esophageal cancer	0.00038	0.00159	CcSEcCtD
Nefazodone—Body temperature increased—Capecitabine—esophageal cancer	0.00038	0.00159	CcSEcCtD
Nefazodone—Convulsion—Methotrexate—esophageal cancer	0.00038	0.00159	CcSEcCtD
Nefazodone—Arthralgia—Methotrexate—esophageal cancer	0.000373	0.00156	CcSEcCtD
Nefazodone—Chest pain—Methotrexate—esophageal cancer	0.000373	0.00156	CcSEcCtD
Nefazodone—Myalgia—Methotrexate—esophageal cancer	0.000373	0.00156	CcSEcCtD
Nefazodone—Discomfort—Methotrexate—esophageal cancer	0.000369	0.00154	CcSEcCtD
Nefazodone—Confusional state—Methotrexate—esophageal cancer	0.000361	0.00151	CcSEcCtD
Nefazodone—Anaphylactic shock—Methotrexate—esophageal cancer	0.000358	0.00149	CcSEcCtD
Nefazodone—Infection—Methotrexate—esophageal cancer	0.000355	0.00148	CcSEcCtD
Nefazodone—Hypersensitivity—Capecitabine—esophageal cancer	0.000354	0.00148	CcSEcCtD
Nefazodone—Thrombocytopenia—Methotrexate—esophageal cancer	0.00035	0.00146	CcSEcCtD
Nefazodone—Hyperhidrosis—Methotrexate—esophageal cancer	0.000346	0.00144	CcSEcCtD
Nefazodone—Asthenia—Capecitabine—esophageal cancer	0.000345	0.00144	CcSEcCtD
Nefazodone—Anorexia—Methotrexate—esophageal cancer	0.000341	0.00142	CcSEcCtD
Nefazodone—Pruritus—Capecitabine—esophageal cancer	0.00034	0.00142	CcSEcCtD
Nefazodone—Hypotension—Methotrexate—esophageal cancer	0.000334	0.0014	CcSEcCtD
Nefazodone—Diarrhoea—Capecitabine—esophageal cancer	0.000329	0.00137	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000326	0.00136	CcSEcCtD
Nefazodone—Insomnia—Methotrexate—esophageal cancer	0.000324	0.00135	CcSEcCtD
Nefazodone—Paraesthesia—Methotrexate—esophageal cancer	0.000321	0.00134	CcSEcCtD
Nefazodone—Dyspnoea—Methotrexate—esophageal cancer	0.000319	0.00133	CcSEcCtD
Nefazodone—Somnolence—Methotrexate—esophageal cancer	0.000318	0.00133	CcSEcCtD
Nefazodone—Dizziness—Capecitabine—esophageal cancer	0.000318	0.00133	CcSEcCtD
Nefazodone—Dyspepsia—Methotrexate—esophageal cancer	0.000315	0.00131	CcSEcCtD
Nefazodone—Decreased appetite—Methotrexate—esophageal cancer	0.000311	0.0013	CcSEcCtD
Nefazodone—Pain—Methotrexate—esophageal cancer	0.000306	0.00128	CcSEcCtD
Nefazodone—Vomiting—Capecitabine—esophageal cancer	0.000305	0.00128	CcSEcCtD
Nefazodone—Rash—Capecitabine—esophageal cancer	0.000303	0.00127	CcSEcCtD
Nefazodone—Dermatitis—Capecitabine—esophageal cancer	0.000303	0.00126	CcSEcCtD
Nefazodone—Headache—Capecitabine—esophageal cancer	0.000301	0.00126	CcSEcCtD
Nefazodone—Feeling abnormal—Methotrexate—esophageal cancer	0.000295	0.00123	CcSEcCtD
Nefazodone—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000292	0.00122	CcSEcCtD
Nefazodone—Nausea—Capecitabine—esophageal cancer	0.000285	0.00119	CcSEcCtD
Nefazodone—Urticaria—Methotrexate—esophageal cancer	0.000284	0.00119	CcSEcCtD
Nefazodone—Body temperature increased—Methotrexate—esophageal cancer	0.000283	0.00118	CcSEcCtD
Nefazodone—Abdominal pain—Methotrexate—esophageal cancer	0.000283	0.00118	CcSEcCtD
Nefazodone—Hypersensitivity—Methotrexate—esophageal cancer	0.000264	0.0011	CcSEcCtD
Nefazodone—Asthenia—Methotrexate—esophageal cancer	0.000257	0.00107	CcSEcCtD
Nefazodone—Pruritus—Methotrexate—esophageal cancer	0.000253	0.00106	CcSEcCtD
Nefazodone—Diarrhoea—Methotrexate—esophageal cancer	0.000245	0.00102	CcSEcCtD
Nefazodone—Dizziness—Methotrexate—esophageal cancer	0.000237	0.000988	CcSEcCtD
Nefazodone—Vomiting—Methotrexate—esophageal cancer	0.000227	0.00095	CcSEcCtD
Nefazodone—Rash—Methotrexate—esophageal cancer	0.000226	0.000942	CcSEcCtD
Nefazodone—Dermatitis—Methotrexate—esophageal cancer	0.000225	0.000941	CcSEcCtD
Nefazodone—Headache—Methotrexate—esophageal cancer	0.000224	0.000936	CcSEcCtD
Nefazodone—Nausea—Methotrexate—esophageal cancer	0.000212	0.000887	CcSEcCtD
Nefazodone—Domperidone—ABCB1—esophageal cancer	0.000188	0.241	CrCbGaD
Nefazodone—Aripiprazole—ABCB1—esophageal cancer	0.000145	0.186	CrCbGaD
Nefazodone—Trazodone—ABCB1—esophageal cancer	0.000144	0.185	CrCbGaD
Nefazodone—Fluphenazine—ABCB1—esophageal cancer	0.000117	0.15	CrCbGaD
Nefazodone—Trifluoperazine—ABCB1—esophageal cancer	9.35e-05	0.12	CrCbGaD
Nefazodone—Quetiapine—ABCB1—esophageal cancer	9.07e-05	0.116	CrCbGaD
Nefazodone—ADRA1A—Signaling Pathways—CXCL2—esophageal cancer	3.7e-05	0.000181	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—NOTCH3—esophageal cancer	3.67e-05	0.00018	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—GHRL—esophageal cancer	3.67e-05	0.00018	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—ALOX15—esophageal cancer	3.67e-05	0.000179	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—XIAP—esophageal cancer	3.66e-05	0.000179	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—FBXW7—esophageal cancer	3.61e-05	0.000177	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—HMOX1—esophageal cancer	3.61e-05	0.000176	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PTGS1—esophageal cancer	3.57e-05	0.000175	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—ENO1—esophageal cancer	3.57e-05	0.000175	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—ALDOB—esophageal cancer	3.56e-05	0.000174	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CA1—esophageal cancer	3.55e-05	0.000173	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—SLC10A2—esophageal cancer	3.55e-05	0.000173	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PSME2—esophageal cancer	3.53e-05	0.000173	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PSME1—esophageal cancer	3.53e-05	0.000173	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PSME1—esophageal cancer	3.52e-05	0.000172	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PSME2—esophageal cancer	3.52e-05	0.000172	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—ANXA1—esophageal cancer	3.52e-05	0.000172	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—TPI1—esophageal cancer	3.5e-05	0.000171	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GSTO1—esophageal cancer	3.5e-05	0.000171	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—ABCB1—esophageal cancer	3.46e-05	0.000169	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CTNNA1—esophageal cancer	3.46e-05	0.000169	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—NOTCH2—esophageal cancer	3.46e-05	0.000169	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PSME2—esophageal cancer	3.46e-05	0.000169	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PSME1—esophageal cancer	3.46e-05	0.000169	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—ANXA1—esophageal cancer	3.44e-05	0.000168	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—NOTCH2—esophageal cancer	3.44e-05	0.000168	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CXCL2—esophageal cancer	3.44e-05	0.000168	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—GAPDH—esophageal cancer	3.43e-05	0.000167	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—SST—esophageal cancer	3.42e-05	0.000167	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	3.42e-05	0.000167	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CRABP1—esophageal cancer	3.39e-05	0.000166	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—ALDOB—esophageal cancer	3.35e-05	0.000164	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—SST—esophageal cancer	3.35e-05	0.000164	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—NOTCH3—esophageal cancer	3.33e-05	0.000163	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—GHRL—esophageal cancer	3.33e-05	0.000163	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—CYP1B1—esophageal cancer	3.32e-05	0.000162	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	3.31e-05	0.000162	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—NOTCH2—esophageal cancer	3.3e-05	0.000161	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—FBXW7—esophageal cancer	3.28e-05	0.00016	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—GHRL—esophageal cancer	3.26e-05	0.000159	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—NOTCH3—esophageal cancer	3.26e-05	0.000159	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CA2—esophageal cancer	3.25e-05	0.000159	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—GNG7—esophageal cancer	3.23e-05	0.000158	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GAPDH—esophageal cancer	3.23e-05	0.000158	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PSME1—esophageal cancer	3.21e-05	0.000157	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PSME2—esophageal cancer	3.21e-05	0.000157	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—FBXW7—esophageal cancer	3.21e-05	0.000157	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CRABP1—esophageal cancer	3.2e-05	0.000156	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—ANXA1—esophageal cancer	3.2e-05	0.000156	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—CYP19A1—esophageal cancer	3.12e-05	0.000152	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—SST—esophageal cancer	3.11e-05	0.000152	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TGFBR2—esophageal cancer	3.07e-05	0.00015	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—EP300—esophageal cancer	3.07e-05	0.00015	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TGFBR2—esophageal cancer	3.05e-05	0.000149	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GNG7—esophageal cancer	3.04e-05	0.000149	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—CYP1B1—esophageal cancer	3.04e-05	0.000149	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—NOTCH3—esophageal cancer	3.03e-05	0.000148	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—GHRL—esophageal cancer	3.03e-05	0.000148	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—ALDH2—esophageal cancer	3.03e-05	0.000148	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PLCE1—esophageal cancer	3.02e-05	0.000147	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ADH7—esophageal cancer	3.02e-05	0.000147	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—NOTCH2—esophageal cancer	2.99e-05	0.000146	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—FBXW7—esophageal cancer	2.98e-05	0.000146	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—NOTCH2—esophageal cancer	2.93e-05	0.000143	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TGFBR2—esophageal cancer	2.92e-05	0.000143	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—SMAD4—esophageal cancer	2.91e-05	0.000142	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—SMAD4—esophageal cancer	2.89e-05	0.000141	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—GSTT1—esophageal cancer	2.88e-05	0.000141	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—CYP19A1—esophageal cancer	2.86e-05	0.00014	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—ALDH2—esophageal cancer	2.85e-05	0.000139	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—HMOX1—esophageal cancer	2.85e-05	0.000139	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CYP2A6—esophageal cancer	2.84e-05	0.000139	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—SMAD4—esophageal cancer	2.77e-05	0.000135	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—ABCB1—esophageal cancer	2.73e-05	0.000133	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—NOTCH2—esophageal cancer	2.72e-05	0.000133	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GSTT1—esophageal cancer	2.71e-05	0.000133	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—ENO1—esophageal cancer	2.7e-05	0.000132	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PTGS1—esophageal cancer	2.7e-05	0.000132	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.69e-05	0.000132	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CYP2A6—esophageal cancer	2.68e-05	0.000131	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PSME1—esophageal cancer	2.66e-05	0.00013	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PSME2—esophageal cancer	2.66e-05	0.00013	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TGFBR2—esophageal cancer	2.65e-05	0.00013	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ADH1B—esophageal cancer	2.65e-05	0.000129	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—HMOX1—esophageal cancer	2.61e-05	0.000127	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TGFBR2—esophageal cancer	2.6e-05	0.000127	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—ENO1—esophageal cancer	2.54e-05	0.000124	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PTGS1—esophageal cancer	2.54e-05	0.000124	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—TYMP—esophageal cancer	2.53e-05	0.000124	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—SMAD4—esophageal cancer	2.51e-05	0.000123	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PSME2—esophageal cancer	2.5e-05	0.000122	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PSME1—esophageal cancer	2.5e-05	0.000122	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—ABCB1—esophageal cancer	2.5e-05	0.000122	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CYP26A1—esophageal cancer	2.46e-05	0.00012	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—SMAD4—esophageal cancer	2.46e-05	0.00012	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TGFBR2—esophageal cancer	2.41e-05	0.000118	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ALOX15—esophageal cancer	2.4e-05	0.000117	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—HIF1A—esophageal cancer	2.38e-05	0.000116	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—HIF1A—esophageal cancer	2.37e-05	0.000116	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—CREBBP—esophageal cancer	2.31e-05	0.000113	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CYP1B1—esophageal cancer	2.29e-05	0.000112	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GSTO1—esophageal cancer	2.29e-05	0.000112	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—TPI1—esophageal cancer	2.29e-05	0.000112	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—SMAD4—esophageal cancer	2.28e-05	0.000112	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—KDR—esophageal cancer	2.27e-05	0.000111	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—PIK3CA—esophageal cancer	2.27e-05	0.000111	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—HIF1A—esophageal cancer	2.26e-05	0.000111	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—KDR—esophageal cancer	2.26e-05	0.000111	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—TP53—esophageal cancer	2.19e-05	0.000107	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ALDOB—esophageal cancer	2.19e-05	0.000107	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—KDR—esophageal cancer	2.17e-05	0.000106	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CYP1B1—esophageal cancer	2.16e-05	0.000106	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CYP19A1—esophageal cancer	2.16e-05	0.000105	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—NOTCH1—esophageal cancer	2.14e-05	0.000105	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—NOTCH1—esophageal cancer	2.13e-05	0.000104	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GAPDH—esophageal cancer	2.11e-05	0.000103	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CRABP1—esophageal cancer	2.09e-05	0.000102	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—NOS3—esophageal cancer	2.07e-05	0.000101	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—HIF1A—esophageal cancer	2.05e-05	0.0001	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—NOTCH1—esophageal cancer	2.04e-05	9.97e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CYP19A1—esophageal cancer	2.03e-05	9.93e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—HIF1A—esophageal cancer	2.01e-05	9.83e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GNG7—esophageal cancer	1.99e-05	9.72e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—HMOX1—esophageal cancer	1.97e-05	9.62e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—KDR—esophageal cancer	1.96e-05	9.6e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CREBBP—esophageal cancer	1.94e-05	9.49e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CREBBP—esophageal cancer	1.93e-05	9.44e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—KDR—esophageal cancer	1.92e-05	9.4e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—EGFR—esophageal cancer	1.91e-05	9.33e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—EGFR—esophageal cancer	1.9e-05	9.28e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PTGS2—esophageal cancer	1.89e-05	9.26e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—HIF1A—esophageal cancer	1.87e-05	9.13e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ALDH2—esophageal cancer	1.86e-05	9.11e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—HMOX1—esophageal cancer	1.85e-05	9.06e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—NOTCH1—esophageal cancer	1.85e-05	9.04e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CREBBP—esophageal cancer	1.85e-05	9.04e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—CREBBP—esophageal cancer	1.83e-05	8.92e-05	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—PIK3CA—esophageal cancer	1.82e-05	8.91e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—EGFR—esophageal cancer	1.82e-05	8.88e-05	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—PIK3CA—esophageal cancer	1.81e-05	8.87e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—NOTCH1—esophageal cancer	1.81e-05	8.85e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—KDR—esophageal cancer	1.79e-05	8.73e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—ABCB1—esophageal cancer	1.78e-05	8.7e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GSTT1—esophageal cancer	1.77e-05	8.67e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CYP2A6—esophageal cancer	1.75e-05	8.57e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—NOS3—esophageal cancer	1.74e-05	8.5e-05	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—PIK3CA—esophageal cancer	1.74e-05	8.49e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—NOS3—esophageal cancer	1.73e-05	8.45e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—NOTCH1—esophageal cancer	1.68e-05	8.23e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CREBBP—esophageal cancer	1.68e-05	8.2e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—CREBBP—esophageal cancer	1.67e-05	8.17e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ENO1—esophageal cancer	1.66e-05	8.12e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PTGS1—esophageal cancer	1.66e-05	8.12e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—PIK3CA—esophageal cancer	1.66e-05	8.09e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—NOS3—esophageal cancer	1.66e-05	8.09e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—EGFR—esophageal cancer	1.65e-05	8.06e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—PIK3CA—esophageal cancer	1.65e-05	8.05e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CREBBP—esophageal cancer	1.64e-05	8.03e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PSME2—esophageal cancer	1.64e-05	8e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PSME1—esophageal cancer	1.64e-05	8e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—NOS3—esophageal cancer	1.63e-05	7.99e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—ERBB2—esophageal cancer	1.63e-05	7.95e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—ERBB2—esophageal cancer	1.62e-05	7.91e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—EGFR—esophageal cancer	1.61e-05	7.89e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—PIK3CA—esophageal cancer	1.58e-05	7.71e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—EP300—esophageal cancer	1.58e-05	7.7e-05	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—PIK3CA—esophageal cancer	1.58e-05	7.7e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—ERBB2—esophageal cancer	1.55e-05	7.57e-05	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—PIK3CA—esophageal cancer	1.54e-05	7.54e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CREBBP—esophageal cancer	1.53e-05	7.46e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—NOS3—esophageal cancer	1.5e-05	7.34e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—EGFR—esophageal cancer	1.5e-05	7.33e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—NOS3—esophageal cancer	1.5e-05	7.32e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PTGS2—esophageal cancer	1.49e-05	7.3e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—NOS3—esophageal cancer	1.47e-05	7.19e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CCND1—esophageal cancer	1.44e-05	7.02e-05	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—PIK3CA—esophageal cancer	1.43e-05	7e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—PIK3CA—esophageal cancer	1.43e-05	6.99e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CCND1—esophageal cancer	1.43e-05	6.99e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CYP1B1—esophageal cancer	1.41e-05	6.9e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—ERBB2—esophageal cancer	1.4e-05	6.87e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—PIK3CA—esophageal cancer	1.4e-05	6.85e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CDKN1A—esophageal cancer	1.39e-05	6.79e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CDKN1A—esophageal cancer	1.38e-05	6.76e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—ERBB2—esophageal cancer	1.38e-05	6.72e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PTGS2—esophageal cancer	1.37e-05	6.69e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CCND1—esophageal cancer	1.37e-05	6.69e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—NOS3—esophageal cancer	1.37e-05	6.68e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CYP19A1—esophageal cancer	1.33e-05	6.49e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CDKN1A—esophageal cancer	1.32e-05	6.47e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—EP300—esophageal cancer	1.32e-05	6.46e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—EP300—esophageal cancer	1.32e-05	6.43e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—PIK3CA—esophageal cancer	1.3e-05	6.36e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—ERBB2—esophageal cancer	1.28e-05	6.25e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CREBBP—esophageal cancer	1.26e-05	6.17e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—EP300—esophageal cancer	1.26e-05	6.16e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—EP300—esophageal cancer	1.24e-05	6.08e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CCND1—esophageal cancer	1.24e-05	6.07e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CCND1—esophageal cancer	1.22e-05	5.94e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—HMOX1—esophageal cancer	1.21e-05	5.92e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CDKN1A—esophageal cancer	1.2e-05	5.87e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CREBBP—esophageal cancer	1.19e-05	5.81e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CDKN1A—esophageal cancer	1.18e-05	5.75e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PIK3CA—esophageal cancer	1.17e-05	5.7e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ABCB1—esophageal cancer	1.16e-05	5.69e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MYC—esophageal cancer	1.15e-05	5.63e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MYC—esophageal cancer	1.15e-05	5.6e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—EP300—esophageal cancer	1.14e-05	5.58e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—EP300—esophageal cancer	1.14e-05	5.57e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—NOS3—esophageal cancer	1.13e-05	5.52e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CCND1—esophageal cancer	1.13e-05	5.52e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—EGFR—esophageal cancer	1.13e-05	5.51e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—EGFR—esophageal cancer	1.12e-05	5.48e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—EP300—esophageal cancer	1.12e-05	5.47e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MYC—esophageal cancer	1.1e-05	5.36e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CDKN1A—esophageal cancer	1.09e-05	5.34e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—EGFR—esophageal cancer	1.07e-05	5.25e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—NOS3—esophageal cancer	1.06e-05	5.2e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—EP300—esophageal cancer	1.04e-05	5.08e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PTGS2—esophageal cancer	1.03e-05	5.05e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MYC—esophageal cancer	9.96e-06	4.87e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PIK3CA—esophageal cancer	9.78e-06	4.78e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MYC—esophageal cancer	9.75e-06	4.76e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PTGS2—esophageal cancer	9.74e-06	4.76e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—EGFR—esophageal cancer	9.74e-06	4.76e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PIK3CA—esophageal cancer	9.73e-06	4.76e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—EGFR—esophageal cancer	9.53e-06	4.66e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TP53—esophageal cancer	9.46e-06	4.63e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TP53—esophageal cancer	9.42e-06	4.6e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PIK3CA—esophageal cancer	9.32e-06	4.55e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PIK3CA—esophageal cancer	9.2e-06	4.49e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MYC—esophageal cancer	9.06e-06	4.43e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TP53—esophageal cancer	9.01e-06	4.4e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—EGFR—esophageal cancer	8.86e-06	4.33e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—EP300—esophageal cancer	8.6e-06	4.2e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PIK3CA—esophageal cancer	8.45e-06	4.13e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PIK3CA—esophageal cancer	8.43e-06	4.12e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PIK3CA—esophageal cancer	8.28e-06	4.04e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TP53—esophageal cancer	8.18e-06	4e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—EP300—esophageal cancer	8.1e-06	3.96e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TP53—esophageal cancer	8.01e-06	3.91e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CREBBP—esophageal cancer	7.78e-06	3.8e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PIK3CA—esophageal cancer	7.69e-06	3.76e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TP53—esophageal cancer	7.44e-06	3.64e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—NOS3—esophageal cancer	6.96e-06	3.4e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PTGS2—esophageal cancer	6.37e-06	3.11e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PIK3CA—esophageal cancer	6.36e-06	3.11e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PIK3CA—esophageal cancer	5.99e-06	2.93e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—EP300—esophageal cancer	5.3e-06	2.59e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PIK3CA—esophageal cancer	3.92e-06	1.91e-05	CbGpPWpGaD
